이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
China Resources Pharmaceutical Group 관리
관리 기준 확인 3/4
China Resources Pharmaceutical Group's CEO는 Xiaosong Bai, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 CN¥ 3.60M, 98.6% 로 구성됩니다. 98.6% 급여 및 1.4% 보너스(회사 주식 및 옵션 포함). 는 HK$ 1.20M 가치에 해당하는 회사 주식의 0.003% 직접 소유합니다. 1.20M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3.7 년입니다.
주요 정보
Xiaosong Bai
최고 경영자
CN¥3.6m
총 보상
| CEO 급여 비율 | 98.6% |
| CEO 임기 | 2.5yrs |
| CEO 소유권 | 0.003% |
| 경영진 평균 재임 기간 | 2.5yrs |
| 이사회 평균 재임 기간 | 3.8yrs |
최근 관리 업데이트
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
보상 대 시장: Xiaosong 의 총 보상 ($USD 495.98K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 452.40K ).
보상과 수익: Xiaosong 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Xiaosong Bai (53 yo)
2.5yrs
테뉴어
CN¥3,601,000
보상
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 2.5yrs | CN¥3.60m | 0.0032% CN¥ 1.1m | |
| VP & Executive Director | 2.8yrs | CN¥2.94m | 데이터 없음 | |
| CFO & Executive Director | 1.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Information Officer & VP | 10.6yrs | 데이터 없음 | 데이터 없음 | |
| Company Secretary | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | 데이터 없음 | 데이터 없음 |
2.5yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: 3320 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 2.5yrs | CN¥3.60m | 0.0032% CN¥ 1.1m | |
| VP & Executive Director | 2.8yrs | CN¥2.94m | 데이터 없음 | |
| CFO & Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 8.1yrs | CN¥270.00k | 데이터 없음 | |
| Non-Executive Director | 2.5yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 8.1yrs | CN¥270.00k | 데이터 없음 | |
| Independent Non-Executive Director | 8.1yrs | CN¥270.00k | 데이터 없음 | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.6yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | 1.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 6.9yrs | CN¥270.00k | 데이터 없음 | |
| Chairman | 4.8yrs | 데이터 없음 | 0.0048% CN¥ 1.7m | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
3.8yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 이사회: 3320 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.